A PYMNTS Company

US: Allergan-KYTHERA deal gets approval

By  |  July 28, 2015

Allergan and KYTHERA Biopharmaceuticals announced that the US Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

The early termination of the waiting period under the HSR Act satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions, including receipt of approval by KYTHERA’s stockholders.

Full content: The Wall Street Transcript

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.